Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027425 · ClinicalTrials.gov registry record · Phase 2
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
A Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, sponsored by Davendra Sohal.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05027425: Active Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, sponsored by Davendra Sohal.
NCT05027425 is a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis that is active but no longer recruiting, run by Davendra Sohal. The registered enrollment target is 30 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05027425, a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, is active but no longer recruiting, sponsored by Davendra Sohal.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
Primary Outcome
To assess the safety of immunotherapy for treatment of HCC in patients listed for a liver transplant, with respect to cellular rejection rates
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- PROCEDURE Liver Transplant
Study Locations (3)
Missouri
- Washington University School of Medicine - St Louis
Ohio
- University of Cincinnati - Cincinnati
Texas
- Simmons Comprehensive Cancer Center UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2030-12-07 |
| Phase | Phase 2 |
What the registry record for NCT05027425 still lists
NCT05027425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT05027425 reports a single indexed study location in Missouri, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT05027425 about?
NCT05027425 is a clinical study titled "Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant". Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
What is the current status of trial NCT05027425?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-12-07. Estimated completion is 2030-12-07.
What conditions does trial NCT05027425 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension.
What interventions are being tested in trial NCT05027425?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), Liver Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT05027425?
This trial is sponsored by Davendra Sohal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05027425 being conducted?
This trial has 3 study locations across Missouri, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05027425's enrollment target sits among peer trials
30 108th of 145 higher than 34 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI